Advancements in Bladder Cancer Diagnosis and Staging: From Cytology to Imaging Techniques

Abstract

Bladder cancer ranks as a prevalent malignancy, especially among men, and is a significant cause of morbidity and mortality globally. This review highlights the epidemiology, diagnostic advancements, and current therapeutic approaches for bladder cancer. Bladder cancer commonly presents as either non-muscle-invasive (NMIBC) or muscle-invasive (MIBC), with distinct pathological stages and treatment goals. The primary diagnostic method for bladder cancer remains cystoscopy, though enhanced techniques such as blue light cystoscopy (BLC) and narrow-band imaging (NBI) have improved lesion detection. Diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), are critical for staging and assessing metastasis. Additionally, urine cytology and fluorescence in situ hybridization (FISH) provide valuable cytopathological insights, enhancing diagnostic accuracy. Innovative diagnostic approaches, including the Paris System for urinary cytopathology and fluorescence urine cytology, have advanced early detection and staging of bladder cancer. Comprehensive understanding and continuous advancements in these diagnostic and therapeutic modalities are crucial for effective patient management and improved clinical outcomes.